Bridgebio Pharma, Inc. · NASDAQ:BBIO

Bridgebio Pharma — Technical Presentation (August 2025)

8 slides from Bridgebio Pharma's technical presentation, August 2025

  1. Slide 1: Acoramidis Reduces Cardiovascular Mortality: Results Through Month 42 from the ATTRibute-CM OLE Study

    Acoramidis Reduces Cardiovascular Mortality: Results Through Month 42 from the ATTRibute-CM Open-label Extension Study Kevin M. Alexander,1 Amrut V. Ambardekar,2 Francesco Cappelli,3 Marianna Fontana,4 Ahmad Masri,5 Nitasha Sarswat,6 Keyur Shah,7 Prem Soman,8 Chris Chen,9 Jean-François Tamby,9 Jonat

  2. Slide 2: Introduction

    Introduction ATTR-CM is a progressive cardiomyopathy resulting in substantial cardiovascular morbidity and mortality caused by destabilization of the TTR tetramer 1 Acoramidis is a highly selective, oral TTR stabilizer that achieves near-complete (≥ 90%) TTR stabilization, and is approved in the USA

  3. Slide 3: Objective

    Objective We report data from the OLE of ATTRibute-CM on prespecified secondary outcomes for: 1. Time to CVM up to Month 42 2. Time to CVM or First CVH up to Month 42 CVM, cardiovascular mortality.

  4. Slide 4: ATTRibute-CM OLE Study Design

    ATTRibute-CM OLE Study Design ATTRibute-CM (30 months) OLE OLE endpointsc 89% met eligibility criteria and elected to enroll in Time to first event for CVM, CVM or OLE (n = 389)a first CVH, and first CVHd,e 800 mg acoramidis HCl BID 800 mg acoramidis HCl BID Continuous Key OLE eligibility criteria n

  5. Slide 5: Clinical Characteristics at Entry to the OLE

    Clinical Characteristics at Entry to the OLE Continuous acoramidis Placebo to acoramidis Participant characteristicsa,b n = 263 n = 126 Age, years, mean (SD)c 78.8 (6.50) 79.7 (6.33) Male sex, n (%) 244 (92.8) 115 (91.3) ATTRwt-CM, n (%)d 242 (92.0) 120 (95.2) ATTR-CM duration at randomization,d,e y

  6. Slide 6: Continuous Acoramidis Reduced the Risk of CVM Versus Placebo to Acoramidis

    Continuous Acoramidis Reduced the Risk of CVM Through Month 42 Versus Placebo to Acoramidis (mITT Populationa) 1.0 0.8 Continuous Placebo to acoramidis acoramidis (n = 409) (n = 202) 0.6 probability Survival CVM, n (%) 68 (16.6%) 58 (28.7%) 0.4 Relative risk 42.1% reduction 0.2 Continuous acoramidis

  7. Slide 7: Continuous Acoramidis Reduced the Risk of CVM/First CVH Versus Placebo to Acoramidis

    Continuous Acoramidis Reduced the Risk of CVM/First CVH Through Month 42 Versus Placebo to Acoramidis (mITT Populationa) 1.0 0.8 Continuous Placebo to acoramidis acoramidis (n = 409) (n = 202) 0.6 probability Survival CVM/first CVH, n (%) 157 (38.4%) 124 (61.4%) 0.4 Relative risk 37.5% reduction 0.2

  8. Slide 8: Conclusions

    Conclusions Acoramidis treatment administered for 42 months led to a 42% relative risk reduction in CVM compared with the placebo to acoramidis treatment group Acoramidis treatment administered for 42 months led to a 38% relative risk reduction in time to CVM or first CVH compared with the placebo t

BridgeBio Pharma — Technical Presentation (August 2025) on 6ix